Mutations in the LRRK2 gene were first linked to Parkinson's disease (PD) risk in 2004. Since then, researchers from around the world have advanced our understanding of the mechanisms through which LRRK2 may contribute to PD, leading to the development of three potential LRRK2-targeted therapies that are now being evaluated in clinical trials. Along with colleagues and collaborators, Dr. Dario Alessi has pioneered new research and approaches that have aided in the development of drugs to inhibit LRRK2 and potentially treat people with Parkinson's disease. In this episode Dario discusses his work developing the LRRK2 kinase assay, LRRK2 Ser935 dephosphorylation assay, and Rab phosphorylation assay, as well as future directions and opportunities in the field. This year, Dario received the 2023 Robert A. Pritzker Prize for Leadership in Parkinson’s Research for his substantial research contribution and his commitment to mentoring the next generation of Parkinson’s scientists. Dario is the Professor of Signal Transduction and Science Director of the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee.

Mentioned in this episode:

The Foundation’s landmark research study is exploring the connection between sense of smell and brain disease. People with and without Parkinson's can help by taking a free scratch-and-sniff test. Get yours at mysmelltest.org/request.

This podcast episode was part of a limited series created by The Michael J. Fox Foundation in 2023 and 2024 for clinicians and researchers in our audience.  These episodes provide a deeper dive into exciting new scientific research in Parkinson’s disease, as well as innovative tools and valuable resources, through conversations with a variety of experts in the field. We hope you enjoy the conversation.